Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins

Martin C. Boonstra[1], Susanna W.L. de Geus[1], Hendrica A.J.M. Prevoo[1], Lukas J.A.C. Hawinkels[2], Cornelis J.H. van de Velde[1], Peter J.K. Kuppen[1,3], Alexander L. Vahrmeijer[1] and Cornelis F.M. Sier[1,3]

[1]Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands. [2]Department of Gastroenterology, Leiden University Medical Center, Leiden, the Netherlands. [3]Antibodies for Research Applications BV, Gouda, the Netherlands.

ABSTRACT: Tumor targeting is a booming business: The global therapeutic monoclonal antibody market accounted for more than $78 billion in 2012 and is expanding exponentially. Tumors can be targeted with an extensive arsenal of monoclonal antibodies, ligand proteins, peptides, RNAs, and small molecules. In addition to therapeutic targeting, some of these compounds can also be applied for tumor visualization before or during surgery, after conjugation with radionuclides and/or near-infrared fluorescent dyes. The majority of these tumor-targeting compounds are directed against cell membrane-bound proteins. Various categories of targetable membrane-bound proteins, such as anchoring proteins, receptors, enzymes, and transporter proteins, exist. The functions and biological characteristics of these proteins determine their location and distribution on the cell membrane, making them more, or less, accessible, and therefore, it is important to understand these features. In this review, we evaluate the characteristics of cancer-associated membrane proteins and discuss their overall usability for cancer targeting, especially focusing on imaging applications.

KEYWORDS: cancer imaging, biomarker, transmembrane, adhesion protein, receptor, GPI anchor

Introduction

Tumor targeting is a relatively novel but rapidly expanding technique applied for cancer treatment as well as visualization. Targeted anticancer therapies consist generally of antibodies or antibody-derived fragments, proteins, peptides, small molecule inhibitors, or DNA/RNA aptamers directing an attached drug to the tumor cell.[1,2] Just the global therapeutic monoclonal antibody market alone accounted already for more than $78 billion in 2012, indicating the potential of targeting for research and development.[3] Of this total amount, 75% was spent for arthritis and cancer, with Remicade, Avastin, Rituxan, Humira, and Herceptin respectively being the top five mega sellers.

Tumor targets are in general membrane proteins or, in some cases, their ligands, with enhanced expression on tumor or tumor-associated cells, such as malignant cells, angiogenic endothelial cells, or inflammatory cells.[2] Besides therapy, the targeting component of these drugs is in principle also suited for the development of tumor-visualizing tracers, which could be used for the early diagnosis or localization of tumors before or during surgery. Generally, all membrane proteins that are overexpressed on tumor or tumor-associated cells are potentially suitable for tumor-targeted imaging. Out of the ~7,000 known transmembrane proteins, ~150 are overexpressed on tumor cells

or tumor-associated vessels, which makes them potential candidates for therapeutic targeting or imaging.[4] However, there is surprisingly little knowledge about which targets should be used for optimal results per tumor type, or even better, per individual tumor or patient.[5,6] To date, most of the imaging probes have been designed to target the vast majority of tumors. The development of personalized probes, customized for specific tumor types, will be inevitable for optimal clinical applications and will require more specific knowledge about tumor targets.

This overview of possible tumor targets is primarily based on the prioritization list of cancer antigens issued by the National Cancer Institute (NCI).[7] In this list consisting of 75 proteins, only 13 members are actually cell membrane-associated proteins. Seven of these proteins are receptors and three are linked to the cell via a glycosylphosphatidyl inositol (GPI) anchor. The other membrane proteins in the list comprise two enzymes, an adhesion molecule, and a glycoprotein with a lubrication/barrier/signaling function (Table 1). To put the various targeting candidates into perspective, the following section provides an overview of each subgroup of membrane proteins. The focus will be on the general characteristics with respect to their function, type of anchorage, and behavior within the cell membrane. For each subgroup, we highlight

Table 1. Characteristics of tumor-associated membrane proteins.

PROTEIN	NCI RANK	FUNCTION	SOLUBLE FORM (REF)	NUMBER PER (TUMOR) CELL (REF)		THERAPEUTIC ANTIBODY	CLINICAL TRIAL# (PHASE)
αvβ3 integrin	–	A	U	$3*10^3–1.4*10^4$	Endothelium[159]	Etaracizumab	F (II)
Bombesin R	–	RG	U	$10^3–10^4$	Prostate[160]		N
CAIX	57	E	Y[161]	**$3*10^5$**	**Colon (*)**	Girentuximab	O, F (II)
CEA	13	A	Y[162]	10^6	Colon[163]	Labetuzumab Arcitumomab Besilesomab Altumomab	F (II) F (II) F, O (III) N
CD13	–	E	Y[164]	10^4	Macrophage[165]		N
CD44, v6	–	A	Y[166]	$7*10^5$	Head/neck[167]	Bivatuzumab	N (I)
CXCR4	–	RG	U	$5000–10^5$	Breast[168]	BMS-936564	O (I)
EGFR	5	RT	Y[147]	$10^3–5*10^4$	Head/neck, breast[167,169]	Cetuximab Imgatuzumab Panitumumab Nimotuzumab Matuzumab Futuximab Necitumumab Zalutumumab	O, F (C) N F, O (II) F, O (II) F (II) O (II) F, O (II) F, O (II)
ErbB-2, Her2	6	co-RT	Y[170]	**$8*10^5–10^6$**	Breast[171,172]	Trastuzumab Pertuzumab Ertumaxomab	O, F (II) O (II) T, O (I/II)
Emmprin	–	A?	Y[173]	$6*10^5$	Pancreas[174]	Metuximab Gabilimomab	O (I) N
Endoglin	–	co-R	Y[175]	**$6*10^5–10^6$**	Endothelial cells[176]	TRC105	O, F (I)
EpCAM	29	A	Y[177]	**$10^4–5*10^5$**	**Colon (*)[178]**	Adecatumumab Edrecolomab Citatuzumab Oportuzumab Solitomab Tucotuzumab Catumaxomab	F (II) O, F (III) N N N F (II) F, O (II)
EphA2	25	RT	Y[179]	**$10^3–10^5$**	Ovary, melanoma[180]	MEDI-547 Dasatinib KB004	T (I) O (II) O (I/II)
FAP-α	72	E	Y[181]	10^5	CAF[182]	Sibrotuzumab F19	N (I) F (I)
Folate R	–	R	Y[183]	10^6	Ovary[184]	Farletuzumab	T, F (I)
GRP78	–	co-R	U	$3*10^5$	Endothelial cells[185]	PAT-SM6	F (I)
IGF-1R	–	R	U	**$2*10^3$**	**Colon (*)**	Cixutumumab Figitumumab	O, F (II) F, T (I)
Matriptase	–	E	Y[186]	**$2*10^5$**	**Colon (*)**		N
Mesothelin	42	A	Y[119]	$< 1000–2*10^5$	Mesothelioma[187]	Amatuximab	T, F (I)
cMET/HGFR	–	RT	Y[188]	10^5	Lung[189]	Rilotumumab Onartuzumab Ficlatuzumab	F, O (III) F, O (I) F (I)
MT1-MMP	–	E	U	N			N
MT6-MMP	–	E	Y[140]	N			N
Muc-1	2	R?	Y[190]	$10^5–10^6$	Breast[191]	Cantuzumab Clivatuzumab	N O (III)
PSCA	43	R, A	Y[192]	N		AGS-1C4D4	F, O (II)
PSMA	11	E	Y[193]	$10^4–10^5$	Prostate[72]	Capromab J591	F, O (I) F, O (II)
Tn antigen	50	GI	Y[194]	N			N
uPAR	–	R, A	Y[195]	10^5	Colon[196]	ATN-658	N

Notes: This table shows the National Cancer Institute ranking of membrane-associated proteins amongst 75 cancer antigens, Cheever, *Clin Cancer Res*, 2009.[6] The indicated numbers per cell are determined with various techniques and therefore difficult to compare, but the numbers in bold are measured using the same procedure (Qifikit, Dako). #Sources: https://clinicaltrials.gov and https://www.clinicaltrialsregister.eu; *M.C. Boonstra, unpublished results.
Abbreviations: A, adhesion; E, enzyme; R, receptor; RT, receptor of tyrosine kinase type; RG, receptor of G-protein type; NM, nonmembranous; G, ganglioside; GI, glycan; N, not done/known; O, ongoing; F, finished; T, terminated; U, unknown; S, soluble form; CAF, cancer-associated fibroblast.

the proteins from the NCI prioritization list, complete with interesting/important targets from the recent literature. The review concludes with a general section on the optimal characteristics of tumor-imaging targets, followed by a paragraph on future perspectives.

Types and Functions of Membrane Proteins

Based on their topology and structure, membrane proteins are historically categorized as subclass types I, II, III, IV, or V.[8,9] Most eukaryotic membrane proteins belong to type I or type III, with respectively one or multiple transmembrane spanning domains. Type II membrane proteins span the membrane similar to type I, but in an opposite orientation, ie, with the amino terminus within the cytoplasm. Type IV and V membrane proteins are anchored to the cell via a chain of lipids or a GPI module (Fig. 1). For this overview, we use a slightly adapted classification, subdividing membrane proteins based on their biological functions into the following: A) receptors, B) cell adhesion or anchoring proteins, C) cell membrane-associated enzymes, D) transporter proteins, and E) GPI proteins[4] (schematic overview is provided in Fig. 2). Because not all of these groups are equally associated with enhanced expression levels in neoplastic growth, we primarily focus on tyrosine kinase receptors (TKRs), G-protein-coupled receptors (GPCRs), cell adhesion molecules (CAMs), membrane-bound enzymes, and GPI-anchored proteins.[7] Although transporter proteins are also reported to be upregulated in cancer cells, they have not been extensively studied for therapeutic tumor targeting yet and are

not present in the NCI list. Because the glucose transporter proteins of the GLUT family are actually the targets for the majority of positron emission tomography (PET)-based tumor imaging research, based on the uptake of the glucose analog ^{18}F-fluorodeoxyglucose (FDG), GLUT1 is included in this overview. Moreover, transporter proteins ABC (ATP-binding cassette), SLC5a* (sodium/glucose cotransporter-5a), and more recently TRPM8 (transient receptor potential cation channel subfamily M, member 8; Fig. 3) seem to have potential for imaging purposes as well.[10,11] A number of membrane-associated antigens from the NCI list are not proteins, but these are mentioned in a separate section.

Receptors.

Tyrosine kinase receptors. TKRs are type I transmembrane receptors that become activated through binding of the extracellular domain with its specific ligand (Fig. 2A). The consequent activation/phosphorylation of the intracellular domain leads to the onset of various pathways, ultimately culminating in a specific response. The 58 known TKRs consist of receptors for growth factors, cytokines, and hormones. A substantial number of TKRs are upregulated in neoplastic tissues, and they play pivotal roles in cancer biology during tumor development, proliferation, angiogenesis, and metastasis. Many studies have explored the potential application of interference of TKRs or their ligands for therapeutic anticancer purposes. Prominent cancer-associated TKRs are the members of the epidermal growth factor receptor family (EGFRs or ErbBs), Eph receptors, fibroblast growth factor receptors, hepatocyte growth factor receptor (HGFR or cMET), insulin-like growth factor (IGF) receptors, and vascular endothelial growth factor receptors (VEGFRs), which are discussed herein.

EGFR (ErbB-1) is upregulated in most cancer types and, therefore, is considered an attractive tumor target (NCI: position **5**/75, Table 1). Anti-EGFR humanized antibodies such as cetuximab, panitumumab, and matuzumab, as well as antibody-derived fragments (Fabs, scFvs, and nanobodies), are extensively used or evaluated for therapeutic and imaging purposes in various types of cancer.[12] Although EGFR is upregulated in a broad range of tumor types including colon cancer, it is not necessarily useful as a target in every individual cancer, as shown in an example in Figure 3.

In comparison to the relatively omnipotent EGFR/ErbB-1, another member from the EGFR family, HER2 (ErbB-2) (NCI **6**/75, Table 1), is predominantly upregulated in relatively small and specific subsets of breast and stomach carcinomas (10%–20%) and is therefore the target of choice for those specific tumors, but it is not particularly suited as a universal tumor-imaging target. Although classified as a receptor, a corresponding soluble ligand has not been identified.[13]

EphA2 (NCI: **25**/75, Table 1) is a member of the largest subgroup of TKRs, the Eph family. Binding of the EphA2 receptor to its ligand EphrinA, located on the membrane of

A Transmembrane   **B** GPI-anchor

Signaling proteins

Figure 1. The essential difference in protein attachment to the cell membrane and the impact on signaling between **A**) transmembrane receptors and **B**) GPI-anchored receptors. The arrows indicate binding of ligands and/or additional adaptor protein, needed for signal transduction via signaling proteins.
**Abbreviation:** GPI, glycosylphosphatidyl inositol.

A Receptors **B** Cell adhesion **C** Enzymes **D** Transporters

TKR GPCR

Figure 2. Schematic representation of diverse groups of membrane-associated proteins. (**A**) Receptors of tyrosine kinase receptor (TKR) and G-protein-coupled receptor (GPCR) subtypes, (**B**) cell anchoring proteins, **C**) enzymes, and **D**) transporter proteins. The respective extracellular ligands, binding proteins, substrates, and transported substances are indicated for each group.

adjacent cells, leads to classical TKR-mediated cell signaling. EphA2 is expressed at low levels in adult normal tissues but is overexpressed in several cancer types. Increased EphA2 tumor levels are associated with worse patient survival.[14,15] Various therapeutic approaches are being evaluated based on EphA2, including the use of monoclonal antibodies, RNA interference, immunotherapy, adenoviral vectors, nanoparticles, and

kinase inhibitors. Although promising, most of these targeted probes are still in the preclinical phase or are being evaluated in early-stage clinical trials.[16]

VEGFR2 (NCI: **70**/75), a receptor of vascular endothelial growth factor (VEGF), is not primarily expressed by cancer cells but by angiogenic endothelial cells in the tumor stroma. Because almost all tumors rely on these cells for

Figure 3. Sequential sections from a representative human colon cancer tissue immunohistochemically stained for various types of membrane-associated proteins. Examples of all the functional groups are presented: tyrosine kinase receptors, epidermal growth factor receptor (EGFR), and hepatocyte growth factor receptor (cMET), C-X-C chemokine receptor-4 (CXCR4) representing the G-protein-coupled receptors (GPCRs), glycosylphosphatidyl inositol (GPI)-anchored receptor urokinase-type plasminogen activator receptor (uPAR), coreceptor endoglin, anchoring proteins carcinoembryonic antigen (CEA) and epithelial cell adhesion molecule (EpCAM), membrane-associated enzyme membrane type-1 matrix metalloproteinase MT1-MMP/MMP14, transporter protein TRPM8 (Transient receptor potential cation channel subfamily M member 8), and the relocalized endoplasmatic reticulum protein glucose-regulated protein-78 (GRP78) (unpublished data, magnification 400×).

oxygen and nutrients transport, VEGFR is considered a universal target for a broad range of tumor types. The promising therapeutic results with antibodies against VEGF, such as bevacizumab (Avastin®), are a good indication of what VEGFR-specific antibodies such as icrucumab (against VEGFR1) and ramucirumab (against VEGFR2) could achieve for imaging applications as well. These antibodies do not rely on VEGFR occupation by VEGF, presumably resulting in higher tumor imaging ratios than those obtained with the well-known therapeutic antibody bevacizumab/Avastin.[17]

Two other promising TKRs for targeting are the HGFR (cMET; Table 1) and IGF-1 receptor (IGF-1R). The WNT pathway target gene cMET is overexpressed in various tumor types, including colorectal cancer, as illustrated in Figure 3.[18] Several cMet-targeting therapeutic modalities, such as antibodies, hepatocyte-specific inhibitors, small inhibitory molecules, peptides, and even HGF (fragments), the natural ligand of cMet, are already in clinical trials.[19–21] This wide range of available interfering compounds is also under evaluation for tumor imaging, with promising results.[22,23]

Similar to cMet, IGF-1R also is upregulated on the surface of various types of cancer cells.[24] Several monoclonal antibody-based studies have evaluated the therapeutic possibilities. The close resemblance with the insulin receptor and concomitant cross-reactivity might hamper the development of IGF-1R-based therapy. The practical use for imaging purposes is under investigation.[25,26]

G-protein-coupled receptors. GPCRs, also known as seven-transmembrane domain receptors, are type III transmembrane receptors located completely intramembranously with the exception of the binding loops (Fig. 2A). The GPCRs comprise approximately 3% of the encoded products of human genes, suggesting the existence of approximately 800 human GPCRs.[27] Individual cells can express up to more than 100 different GPCRs that are involved in the regulation of various cellular processes.[28] The ligands that activate receptor response are diverse, varying from hormones to neurotransmitters. Several GPCRs are clearly associated with cancer and, because interfering with GPCRs is relatively easy, one-third of all current therapeutics are actually directed against this type of receptors.[5,29] Various clinical trials for GPCR-targeting drugs against different types of cancer are under evaluation, eg, atrasentan, zibotentan, and vismodegib.[30,31] Yet, none of these GPCRs are in the NCI prioritization list of cancer targets. C-X-C chemokine receptor-4 (CXCR4), protease-activated receptor (PAR)-1, follicle-stimulating hormone receptor (FSH-R), glucose-regulated protein (GRP), and procaspase activating compound (PAC)-1 seem to be the most prominent upregulated components in breast, head and neck, lung, ovarian, prostate, and colon cancer and are therefore evaluated as candidates for imaging applications.[32] CXCR4 (Table 1) is the receptor for SDF1/CXCL12 and is implicated in the cross talk between (tumor) cells and their microenvironment. Overexpression has been found in all major tumor types, including colon cancer (Fig. 3).[33] Antibodies and peptides against CXCR4 are extensively being evaluated for molecular imaging purposes, with promising results.[34] PAR-1, a member of the protease-activated receptor subfamily, and FSH-R are mainly overexpressed on endothelial cells within the tumor environment and would therefore also be present in a broad range of tumors. PAR-1 has already been evaluated for in vivo imaging of angiogenic endothelial cells and malignant cells.[35] The abundant expression of FSH-R in angiogenic blood vessels, as recently shown in large numbers of tumors, would make this receptor a broadly applicable tumor-detecting target for the imaging of especially larger tumors.[36,37]

A number of GPCRs, including the receptors for somatostatin, gastrin, bombesin, and cholecystokinin (CCK), are already being clinically exploited for the diagnosis of neuroendocrine tumors (Table 1). Neuroendocrine tumors consist of a heterogeneous group of neoplasms, including carcinoids, pancreatic islet tumors, paragangliomas, and neuroblastomas, for which surgery is the only curative treatment. Accurate localization with radiolabeled peptide analogs of somatostatin, gastrin, bombesin, and CCK is used to target their respective GPCRs.[38,39] The adaptation of these tracers with near-infrared (NIR) labels might lead to a wider application in cancer imaging, possibly also for more common tumors.[40]

Cell adhesion molecules. CAMs form a large and diverse group of membrane-bound proteins that are defined as morphoregulatory molecules that affect cellular processes. The definition indicates that these proteins are not implicated only in cell–cell or cell–matrix adhesion as the name suggests (Fig. 1B).

Carcinoembryonic antigen (CEA; NCI: **13**/75, Table 1) and the CEA-related adhesion molecules (CEACAMs) form an important family of transmembrane glycoproteins. They are involved in the regulation of cell growth, differentiation, immune response, and cell adhesion.[41] Specifically, CEA, CEACAM5, and CEACAM6 have been associated with cancer.[42] CEA is physiologically expressed on gastrointestinal cells during fetal development but is not expressed after birth, except on tumor cells of various origins (Fig. 3).[43] CEA, CEACAM6, and CEACAM8 are anchored to the cell membrane via a GPI module. This type of anchorage makes them more vulnerable to shedding from the membrane, leading to a soluble form of CEA, which is used as a diagnostic or screening tool for colorectal cancer patients. Although promising preclinical studies have been presented, the presence of high soluble levels in the circulation (0–2.5 µg/L) should be taken into account as possible scavengers if these proteins are considered for tumor targeting in patients.[44–47] The general pros and cons of GPI-anchored proteins are discussed later.

Two CAMs that are highly associated with tumor proliferation and overexpression are EpCAM (epithelial cell adhesion molecule) and E-cadherin. EpCAM (NCI: **29**/75, Table 1)

is overexpressed on the cell surface of the majority of primary (Fig. 3) and metastatic cells and is therefore considered a universal tumor marker.[48–50] Consequently, a substantial arsenal of anti-EpCAM targeting compounds has been developed, including designed ankyrin repeat proteins (DARPins), RNA aptamers, scFv-coated nanocarriers, and a number of anti-EpCAM humanized monoclonal antibodies.[51] Some of these antibodies have already been evaluated for immunotherapy in clinical trials, but the results are diverse, and further research is necessary to evaluate their potential for anticancer treatment.[51–55] More recently, several preclinical studies have indicated the potency of EpCAM as a target for the imaging of tumors.[56,57] E-cadherin is essential for the formation of intercellular junctions and therefore generally considered a tumor suppressor. However, recent studies associate increased E-cadherin with the greater aggressiveness of certain tumor types, eg, ductal breast and ovarian carcinomas.[58] However, although E-cadherin has been considered a tumor target,[59] the fact that tumor cells undergoing epithelial-to-mesenchymal transition (EMT) do not express E-cadherin, or express it only intracellularly, limits the clinical use of this protein.[60]

Another important family of CAMs are the integrins. They consist of heterodimer receptors involved in the regulation of the cell cycle, cellular shape, and motility, due to their interaction with other cells and with the extracellular matrix.[61] Specifically, integrins containing the alpha subunit are abundantly overexpressed in tumors, both on angiogenic endothelial cells, eg, $\alpha v\beta 3$ (Table 1), as well as on malignant epithelial cells, eg, $\alpha v\beta 3$, $\alpha v\beta 5$, and $\alpha v\beta 6$.[62–64] Targeting of a number of integrins simultaneously via an arginyl-glycyl-aspartic acid (RGD) peptide is well established and is being explored for both tumor imaging and therapeutic purposes.[65–67]

Cell membrane-associated enzymes. An interesting group of possible tumor targets are the membrane-associated enzymes (Fig. 1C). This is a rather heterogeneous group of proteins primarily involved in the maintenance of cellular functions, uptake/secretion/proteolysis of proteins, and extracellular matrix remodeling. They are important for the homeostasis of the cell and regulate cell–cell and cell–matrix contacts. Upregulation under neoplastic conditions has been reported for a number of these enzymes, especially the proteases that are involved in extracellular matrix remodeling during migration and invasion.

Glutamate carboxypeptidase 2, also known as folate hydrolase 1 (FOLH1) or prostate-specific membrane antigen (PSMA; NCI: **11**/75, Table 1) is a type II membrane-bound peptidase found primarily in prostate tissues. PSMA is abundantly upregulated on prostate carcinoma cells and on the neovasculature of most other solid tumors and is therefore considered a functional tumor target. The enzyme's carboxypeptidase activity is involved in the release of several proteins from the cell, eg, folate, and is currently being evaluated for activation of prodrugs or imaging agents.[68] Labeled inhibitors,

peptides, and monoclonal antibodies against PSMA have been studied as imaging agents, with positive results.[69–71] Therapeutic approaches using conjugates of targeting determinants against PSMA with cytotoxic drugs are under investigation.[72,73]

Another type II membrane-bound peptidase that is investigated as a potential tumor target is aminopeptidase N, also known as CD13 (Table 1). This enzyme is abundantly expressed on fast-growing angiogenic endothelial cells but is also present on tumor cells.[74] Aminopeptidase N serves as a receptor for Asn-Gly-Arg (NGR) peptide(s). NGR peptides are intensively evaluated as a tumor target for both therapy and imaging.[75,76] Clinical trials with NGR peptides conjugated to toxins or antitumor cytokines such as tumor necrosis factor (TNF) are under investigation.[77] As for PMSA, imaging of aminopeptidase N could be established by binding of a determinant to the protein, such as NGR peptide, but could also be based on the local proteolytic activity of the enzyme.[78,79]

Furthermore, overexpression of seprase and matriptase, two members of the transmembrane serine protease family, has been associated with several tumor types, including breast, colon, ovary, and prostate cancer.[80,81] Seprase or fibroblast activation protein (FAP-α; NCI: **72**/75, Table 1) is mainly expressed on activated stromal fibroblasts in the stroma of various tumor types. Cancer-associated fibroblasts (CAFs) are still relatively unexplored as targets for cancer therapy/imaging, but their presence in various tumor types suggests a broad applicability. Preclinical studies using FAP-α-targeting agents have already indicated the potential of the mentioned proteins and CAFs for cancer imaging.[82,83]

Matriptase (membrane-type serine protease 1, MT-SP1, Table 1) is enhanced in several tumor types, where it is suggested to play an active role via the activation of HGF and urokinase plasminogen activator.[84] NIR fluorescence and radiolabel imaging of antibodies against the active form of matriptase showed a tumor-specific signal in animal models, indicating that these membrane-bound enzymes, as well as their activities, could be used for tumor imaging.[81]

The matrix metalloproteinases (MMPs) and the ADAMS (A disintegrin and metalloprotease domain) are the most prominent families of invasion-associated proteases. Two transmembrane members, membrane type-1 matrix metalloproteinase (MT1-MMP)/MMP14 (Fig. 3) and ADAM12, have been found to be upregulated in various types of cancer.[85] Targeting of MMP14 with a radiolabeled antibody confirmed the potential of this membrane protein as a tumor target.[86] As already indicated for PSMA and aminopeptidase N, an advantage of choosing proteolytic enzymes as a tumor target is the possibility of making use of their main feature, ie, activation of substrates. Several targeting drugs and imaging probes have been developed using upregulated membrane-bound or membrane-associated proteolytic enzymes, such as MMP-2, MMP-7, and MMP-9, for localized activation.[87,88] Recently, first-in-human

data have been presented for a cathepsin-activated probe, underscoring the potential of this approach.[89]

Proteolytic enzymes are not the only molecules studied as tumor-specific targets. Carbonic anhydrase nine (CAIX; NCI: **57**/75, Table 1) is a hypoxia-induced enzyme located on the cell membrane and it plays a role in extracellular pH regulation. Because excessive cell growth is associated with acidification of the extracellular environment, many cancer cells from various tumor types express enhanced levels of CAIX.[90] For several decades, two monoclonal antibodies, G250 and M75, have extensively been evaluated as tumor-targeting tools,[91] especially conjugated to radiolabels,[92] but recently also with NIR-fluorescent (NIRF) probes, enabling visualization of the otherwise difficult to identify ductal carcinoma in situ of the breast (DCIS) in an animal model.[93] The localization within hypoxic, more central regions of the tumor might hamper the use of this target for NIR imaging purposes.

Transporter proteins, mucins, and other membrane-associated proteins.

Transporter proteins. Due to their changed physiology, most malignant cells show enhanced metabolic activity. Cell membrane transporter proteins such as GLUT, ABC, and SLC5a* are upregulated on cancer cells, compared to adjacent normal cells. High levels of glucose transporters GLUT1/GLUT3/GLUT12 are found in a wide range of solid tumors correlating with poor survival.[94] Overexpression of GLUT proteins is often associated with hypoxic conditions and is generally present in perinecrotic areas within the tumors. Being the main glucose transporters, the GLUT proteins are the targets of one of the most commonly used oncologic PET tracers, FDG (2-deoxy-2-[18F]fluoro-D-glucose). Although efficient for PET imaging of many tumor types, due to the commonly encountered high uptake in normal tissues and the expression pattern within the tumor, GLUT proteins seem not particularly suited for NIRF imaging.

Although aberrant expression of channels for ions such as Ca, Na, and K is a common feature of tumor cells, there are relatively few studies dedicated to the use of these membrane proteins for tumor targeting yet.[10,11] An example of a potential candidate for tumor targeting is TRPM8.[95,96] TRPM8 is aberrantly present on various types of cancer cells, including breast, lung, colorectal and pancreatic cancer, where it seems essential for the expanding growth of several types of tumors (Fig. 3).

Mucins and other difficult-to-categorize membrane-associated proteins. The highest ranked membranous protein in the NCI prioritization list is epithelial membrane antigen (EMA), also known as mucin-1 (MUC-1; NCI: **2**/75, Table 1). MUC-1 is a member of a family consisting of 21 highly glycosylated proteins, among which only some are transmembranous (MUC-1, -4, -13, -16), while the others are secreted. Mucins are involved in the protection of the apical surface of glandular epithelial cells and are therefore not easily categorized based on their function. Overexpression and underglycosylation of

MUC-1, together with relocalization to the entire cell surface, have been reported for almost all epithelial carcinomas, including 90% of breast tumors. As a result, core epitopes become exposed on these cancer cells and can be targeted for both imaging and therapy. Although relatively few considering the NCI rating, several approaches are being evaluated to target MUC-1 therapeutically, including antibodies (fragments), peptides, and nucleic acid aptamers,[97,98] some of which are also under evaluation for various imaging applications.[99–101]

Extracellular matrix metalloproteinase inducer (EMMPRIN), also named basigin or CD147, is another example of a type I transmembrane glycoprotein that does not fit within any category based on its function. EMMPRIN acts as a stimulator of MMP synthesis via cell–cell interactions. Because of its prominent expression in pancreatic cancer,[102] EMMPRIN has recently successfully been evaluated for anticancer applications in orthotopic pancreatic cancer murine models[103–106] and for PET imaging.[107]

Some proteins that are generally located within the cell form membranous counterparts under tumor conditions. An intriguing example of the latter is GRP78, a member of the Hsp70 heat shock protein family, also known as BiP. Under normal conditions, GRP78 is present in the endoplasmatic reticulum (ER). Hypoxia or glucose-deprived conditions, as often found in poorly perfused tumor tissues, lead to upregulation of GRP78 and relocalization from the ER into the cytoplasm and the cell membrane, where it functions as a (co)receptor by binding to other membrane proteins.[108,109] Enhanced membranous GRP78 has recently been recorded in most cancer types (Fig. 3), often associated with bad prognosis.[110–112] Because of the tumor-associated membranous expression, GRP78 is regarded as a recognition element for cancer drug targeting, and antibodies are recently being evaluated for use as PET tracer for pancreatic cancer.[111,113]

Endoglin (CD105, Table 1) is a type I transmembrane glycoprotein (co)receptor for various ligands, including bone morphogenetic protein (BMP)-9 and transforming growth factor (TGF)-β, but it does not induce intrinsic kinase activity. Therefore, endoglin does not belong to either the TKR or the GPCR families of receptors. Apart from soluble ligands, endoglin also interacts with high affinity to membrane proteins such as the TGF-β receptors and various integrins.[114] Enhanced endoglin levels seem essential for angiogenesis during tumor development. Because of the low expression in normal tissues, endoglin on tumor-associated neoangiogenic cells is being explored as the target for a wide range of solid tumors (Fig. 3). Monoclonal antibodies against endoglin are being evaluated for anticancer therapy and imaging purposes. Multiple Phase II clinical trials are ongoing with TRC105, an endoglin-neutralizing antibody binding to the extracellular endoglin orphan domain, as antiangiogenic therapy.[115] In addition, TRC105 has also been preclinically applied for the imaging of tumor vasculature in mice cancer models.[116]

In addition to proteins in the cell membrane, a number of nonproteins, such as glycans and phospholipids, are being explored or evaluated as candidate tumor targets. Examples that are associated with tumor targeting are CA19-9, CD77, fucosyl GM1, gangliosides, polysialic acid, GD3, sLe^a/sLe^x, sialyl-Tn antigen, and phosphatidylserine.

GPI- and lipid-anchored proteins. GPI- and lipid-anchored proteins are a relatively small and heterogeneous group of proteins, consisting of receptors and adhesion molecules, which cannot easily be integrated within the conventional classification systems (Fig. 2). They share solely the mode of attachment to the cell membrane.[117] We discuss this group separately in this overview because a relatively large number of GPI-anchored proteins are associated with cancer, among which the already-discussed CEA is the most prominent.[118] Here, we highlight other cancer-associated GPI proteins, namely, mesothelin, prostate stem cell antigen (PSCA), and the receptors for urokinase and folate.

Mesothelin (NCI: **42/75**, Table 1) is normally found on certain mesothelial cells, but overexpression occurs in several cancer types, including tumors of the ovaries, lungs, and pancreas.[119] Mesothelin is probably involved with cellular adhesion. Monoclonal antibodies against mesothelin are being evaluated for the treatment of multiple forms of cancer, showing great potential in preclinical studies.[120,121] Recently, antibody-based dual imaging (single-photon emission computed tomography/magnetic resonance imaging [SPECT/MRI]) has successfully been performed in preclinical models, indicating the possibilities of using mesothelin as tumor target.

PSCA (NCI: **43/75**, Table 1) is a small GPI-anchored protein, mainly present on the epithelial cells of the prostate, with low levels in the urinary bladder, kidneys, and the gastrointestinal tract. Its function is not known, but a role in cell–cell adhesion and cell signaling has been reported. PSCA is overexpressed on the prostate and in pancreatic cancers, but downregulation in tumor cells has also been reported. Clinical applications have mainly been focused on prostate cancer, being overexpressed in 90% of primary tumors and lymph nodes. Anti-PSCA monoclonal antibodies are being evaluated in preclinical studies.[122] PSCA shows some structural resemblance with the receptor for urokinase-type plasminogen activator receptor (uPAR).

uPAR (Table 1) localizes the proteolytic activity of urokinase, important for matrix degradation, but binding of urokinase to its receptor also results in cell signaling. Being a GPI-anchored protein and therefore lacking an intracellular domain, the signaling functions of uPAR are mediated by interactions with other membrane proteins, such as integrins (eg, α5β1), TKRs (eg, EGFR), GPCRs (eg, CXCR4), and matrix components such as vitronectin.[123,124] Upregulation of uPAR levels has been found in the majority of tumor types[124] and was associated not only with malignant cells but also with macrophages, neutrophils, and endothelial cells within the tumor microenvironment.[125] Therefore, uPAR is being

extensively studied as a target for cancer therapy and imaging using antibodies, peptides, as well as the amino terminal fragment derived from the natural ligand urokinase.[126–129] First-in-human results have been presented recently.[130,131]

The folate receptors (FRs) are a set of two GPI-linked membrane proteins (isoforms α and β) absent in most normal tissues but frequently observed in various types of human cancers. FR-α has been considered a target for cancer therapy for more than a decade.[132–135] Recently, various studies have used the natural ligand folate/folic acid, conjugated with NIRF and radioactive labels, for the imaging of various types of human tumors in animal models,[136,137] culminating in the first-in-human imaging studies in ovarian cancer patients.[138,139]

Two members of the previously mentioned metalloproteinase family, MT4-MMP/MMP17 and MT6-MMP/MMP25 are also GPI-anchored moieties and they are upregulated in various cancer types, wherein they are associated with tumor progression.[140,141] The localized proteolytic activity of both MT-MMPs, especially at the interface between tumor and stromal cells, contributes to remodeling of the extracellular matrix, enabling metastatic dissemination.[142,143] Although MMP-activated prodrugs are being investigated for tumor therapy and tumor imaging, they are not specifically designed for GPI-anchored MT-MMPs, lacking (tumor cell) specificity.

Characteristics Defining Good Tumor Targets

In the previous section, a large number of tumor-associated cell membrane proteins have been discussed. Although they all have their specific pros and cons, not all of these proteins are equally good targets for therapy or imaging. Some generic characteristics for target tumor proteins have been defined recently.[7,144] The most obvious criteria, besides the localization on the cell membrane, are the exclusive upregulation on cells within the tumor compared to adjacent normal tissue cells, the actual number of targeted proteins available per cell, and the percentage and distribution of positive cells within the tumor (Fig. 4). Another convenient but not essential criterion would be the presence on a wide variety of tumor types. The presence of high levels of soluble forms of the protein in the circulation could be regarded as disadvantageous. On the other hand, the presence of these proteins in the circulation could be used as indicators for the expression on the tumor, as indicated in Figure 4. In the next part of this overview, some key characteristics of good tumor target proteins will be discussed.

Number of target proteins per tumor cell. Upregulation of the number of target protein molecules is important for distinguishing tumors from normal tissue counterparts (Fig. 4). Two- to 100-fold upregulation levels have been reported for various cell membrane tumor markers. Rough estimations of the total copy numbers of membrane markers per (tumor) cell indicate that there are large differences between proteins and within the various groups of membrane proteins (Table 1). For targeting purposes, upregulation on tumor cells is only

Figure 4. Schematic overview of membrane proteins on normal polarized epithelial cells (left) versus their counterparts on malignant tumor cells (right). The number, distribution, and conformation of cell membrane proteins on normal cells are determined by variables such as presence of ligands, internalization, shedding, and microvesicle formation. Although cancer cells often show enhanced expression of tumor-associated membrane proteins, the suitability as target for imaging of these proteins is often hampered by a changed distribution profile, increased internalization, shedding, and/or microvesicle formation.

relevant if this culminates in significantly high(er) protein numbers per cell compared with cells in the adjacent normal tissue. A recent in vitro study has established a threshold for effective HER2 therapeutic targeting, starting from 2×10^5 receptors per cell.[145] Because HER2 overexpression is due to a genetic amplification of up to 50 gene copies, the number of HER2 molecules on positive tumor cells is 40- to 100-fold upregulated, culminating in levels of over 10^6 copies per cell. With this number, HER2 ranks among the highest expressed membrane proteins, which—together with the low expression levels in nonmalignant cells—renders it an ideal target, but unfortunately only in a relatively small percentage of tumors.[13] Especially for tumor-imaging purposes, the actual number of copies per tumor cell is probably less important than the ratio

of copies between tumor cells and normal cells. Because the number of EGFRs on normal cells is between zero and 40,000 depending on the tissue type, the upregulation on cancer cells to a maximal 10^5 molecules per cell (Table 1) would result in, for some normal tissues, only marginally enhanced levels, whereas for other tissues, this ratio will suffice.[146] Table 1 gives an estimation of the number of copies per cell for many of the proteins discussed in this overview.

Availability/accessibility of the target on the cell membrane. All the discussed membrane proteins are in principle present in enhanced numbers on the membrane of the cell. However, many of these proteins do also have intracellular and/or extracellular variants (Fig. 4). The presence of both variants is not advantageous for tumor targeting. Intracellular

forms are not directly accessible and reduce the number of membrane proteins per cell, except when internalization has occurred after targeting. Internalization is particularly associated with membrane receptors after binding of their specific ligand, but it can also occur with antibodies or other targeting probes. Extracellular forms of membrane proteins can originate from alternatively spliced variants but can also originate from the original membrane proteins after cleavage from the membrane, a process called shedding. These soluble receptors are still capable of binding ligands or antibodies, targeting the latter in the circulation, resulting in the need for higher doses, as indicated for CEA and EGFR.[44,147] In addition to occurring as soluble proteins, extracellular membrane proteins are also present in the circulation on membrane particles called microvesicles (Fig. 4). Microvesicles are particles shed by (tumor) cells ranging in size from 100 nm to 1,000 nm in diameter. They consist of the membrane and cytosolic contents of their parental cells and generally arise from an unspecific spontaneous process. Involvement of microvesicles is indicated in cardiovascular disease, rheumatic arthritis, and cancer.[148] Many of the tumor cell-associated membrane proteins have been identified on microvesicles in the blood of cancer patients. Similar to their soluble counterparts, these membrane proteins scavenge a percentage of the targeting probe.

Even abundant presence on the cell membrane does not necessarily guarantee easy accessibility of a target. Determining factors are the solubility and the clustering of the protein within the membrane, the polarization state of the cell, the presence of various forms of the same protein, and the binding of these proteins to other proteins. All membrane proteins are to some extent able to float freely through the membrane bilayer of a cell, but some are more fluid than others. Because GPI anchors do not completely extend through the plasma membrane, GPI-anchored proteins belong to the most diffusive proteins on the cell surface, allowing a rapid response to external stimuli.[149] High membrane solubility and the highly associated cluster formation in microdomains are considered advantageous for tumor targeting. An example is the GPI-anchored FR-α. After the binding of folate, the receptor clusters in specific cellular membrane subdomains, followed by endocytosis. Intracellular folate dissociates from the receptor and is translocated into the cytoplasm, whereas the receptor recycles rapidly back to the cell membrane, available for the next ligand/probe.[150] Folate derivatives are therefore extensively studied/explored as probes for cancer therapy or imaging.

Normal epithelial cells are strongly polarized, with an apical side and a basolateral side. The distribution of most membrane proteins is strongly dependent on the function, eg, adhesion molecule EpCAM, which is primarily present at cell–cell and cell–matrix contact points. When epithelial cells differentiate to migrating cancerous cells, they generally lose their polarized structure, indicating that specifically arranged membrane proteins are not restricted to the different sides

anymore but become distributed throughout the entire plasma membrane.[48] The conversion of a protein into various confirmation states might also hamper the traceability. For instance, the three-dimensional appearance of receptors changes considerably after the binding of a ligand, affecting the affinity of an antibody or peptide drastically. Adhesion molecules, on the other hand, have various activation states, which also influence the affinity for the targeting probes.[151]

Considerations to Select the Optimal Target for Tumor Imaging in the Clinic

Although tumor imaging during an operation is considered a very powerful technique, the quest for optimal probes/targets for this application has only just begun. In the past 10 years, numerous tumor-targeting NIRF probes are, or have been, evaluated in preclinical animal models with generally good results. The translation of these results into the clinic however, is another story. A recent search for clinical trials using NIR probes revealed almost 80 hits (May 2016, clinicaltrials.gov, near infrared AND cancer/tumor). However, the vast majority of these studies are investigating the use of indocyanine green, a nontargeted dye, to detect sentinel lymph nodes in a wide range of tumor types. Only eight trials are actually using targeted probes, the majority being based on only two therapeutic antibodies targeting VEGF and endoglin, both predominantly present on (tumor) angiogenic cells. These studies are presumably just the tip of the iceberg still to come but indicate the relative immature status of the matter.

This overview of the different groups of cell membrane proteins and possible candidate members for tumor targeting shows that, in principle, many different proteins could be used and that most of them will work to a certain extent, at least in preclinical models. Selecting the best probes from among these candidates requires a systematic comparison of the performance of candidate targets in suitable model systems, preferably for various tumor types. Whether currently available mouse tumor models provide the proper tools to make adequate selections/comparisons of probe/target combinations is still questionable.

Unfortunately, the choice of a target protein is only the beginning. Various studies indicate that antibodies to the same protein show very different results on imaging, depending on the domain of the protein that is targeted or the affinity of the antibody for the protein. Apart from antibodies, there is a whole range of alternatives available, each with specific (dis)advantages. Recently published clinical studies with an antibody (bevacizumab), a natural receptor ligand (folate), and a peptide (cMET) suggest that tumor-targeting agents that were originally designed for cancer therapy might be useful for imaging purposes as well.[23,152,153] Many of these targeting therapeutic agents are now being evaluated for imaging. These agents have been already evaluated in the clinic for side effects and doses, albeit without the NIRF dye or radiolabel being attached. Therefore, these therapeutic agents warrant

a presumably faster translation into the clinic than newly designed imaging probes.

Overall Conclusion and Future Perspective

It should be clear from the previous paragraphs that the ultimate target for tumor targeting has not been found or does not exist. It is even impossible to indicate how it should look like or which subgroup of cell membrane proteins it should belong to. We do not even have proper tools/models to compare the targets/agents properly.

The fact that the majority of the priority proteins from the NCI list belong to the TKR subgroup indicates that these receptors are apparently suited for targeted therapy and/or imaging. The main reason is the large number of these receptors on tumor cells (Table 1). However, this by no means implies that all these receptors are always upregulated in the majority of tumors, as indicated for EGFR in Figure 3. Although one of the most robust targets, for colon tumor, EGFR is clearly outperformed by cMET, another member of the TKR subgroup, and also by CXCR4, MMP14, CEA, TRPM8, and GRP78, members of the GPCR, enzyme, adhesion molecule, transporter protein, and heat shock protein families, respectively.

Despite the prominent presence of soluble counterparts in the circulation, GPI-anchored proteins seem particularly good tumor targets, represented in Figure 3 by CEA, FR, and uPAR. In comparative studies, CEA is generally among the best markers for colorectal tumors and other cancer types.[46] CEA shares this multitumor type distribution with another non-GPI-anchored adhesion molecule EpCAM (Fig. 4A). FR and uPAR are also good examples of pluripotent tumor targets. Although uPAR expression is probably relatively low, it would have the extra advantage that upregulation is not limited to cancer cells only but also extends to stromal tumor cells such as angiogenic endothelial cells and macrophages (Fig. 3).

Targeting of tumor stromal cells rather than malignant cells has great potential, especially for tumor imaging. The initial studies on stromal tumors concentrated primarily on angiogenic endothelium, which is present in the periphery of many tumors. Especially, the αvβ3 integrin has been successfully targeted in many preclinical and clinical studies. In terms of numbers per cell, this adhesion molecule is a rather low-expression-level membrane protein (Table 1), indicating the power of targeting angiogenic cells for tumor imaging. With 10 times more proteins per cell membrane, the TGF-β coreceptor endoglin seems a promising alternative for αvβ3 for angiogenic endothelial targeting.[154]

In conclusion, in the coming years, an enormous boost is expected from the rapidly advancing imaging techniques. The global optical imaging market is expected to reach US$1.9 billion by 2018.[155] These advanced camera systems will rely on high-quality targeting tracers. Better understanding of membrane proteins and their characteristics will

be essential for the development of these compounds, regardless of whether the target is cancer or any other disease. The concept that one probe targeting one single protein will be able to detect all tumors seems too optimistic. Therefore, selecting the right patient/probe combination is of key importance.[156] Circulating soluble forms of targetable membrane proteins could offer a convenient noninvasive way to confirm the presence in the tumor. As previously mentioned, GPI-anchored membrane proteins, such as CEA, FSH-R, and uPAR, shed relatively easily from the cell membrane, which could be an advantage. Most research is focused on single target approaches, but the use of these types of probes has the intrinsic property that they are limited in their applicability for specific patient subgroups.[156] Recent developments suggest that approaches such as agents targeting two proteins, or alternatively two different epitopes on a biomarker (biparatopic), result in considerably higher affinity, specificity, and sensitivity and address the problem of intratumoral heterogeneity.[157,158]

Abbreviations

ABC, ATP-binding cassette; ADAMS, A disintegrin and metalloprotease domain; ATF, Amino terminal fragment; BIP, Binding immunoglobulin protein; CAIX, Carbonic anhydrase-9; CAM, Cell adhesion molecule; CCK, Cholecystokinin; CEA, Carcinoembryonic antigen; CXCL-12, C-X-C chemokine ligand-12; CXCR-4, C-X-C chemokine receptor-4; cMet/HGFR, Hepatocyte growth factor receptor; DARPins, Designed ankyrin repeat proteins; DCIS, Ductal carcinoma in situ; EGF(R), Epidermal growth factor (receptor); EMMPRIN, Extracellular matrix metalloproteinase inducer; EpCAM, Epithelial cell adhesion molecule; Eph(R), Ephrin receptor; ER, Endoplasmatic reticulum; FAP-α, Fibroblastic activation protein-α; FDG, Fluorodeoxy glucose; fMLP, Formyl-methionyl-leucyl-phenylalanine; FR-α, Folate receptor-αa; FSH(R), Follicle-stimulating hormone (receptor); GLUT, Glucose transporter; GPCR, G-protein-coupled receptor; GPI, Glycosylphosphatidyl inositol; GRP-78, Glucose-regulated protein-78; HER2, Human epidermal growth factor receptor-2, ErbB-2; HGF(R), Hepatocyte growth factor receptor; HSP-70, Heat shock protein-70; IGF-1R, Insulin-like growth factor-1 receptor; MMP, Matrix metalloproteinase; MUC-1, Mucin-1; NCI, National Cancer Institute; NGR peptide, Asn-Gly-Arg peptide; NIR(F), Near-infrared fluorescence; PAC-1, Procaspase activating compound-1; PAR-1, Protease-activated receptor-1; PSCA, Prostate stem cell antigen; PET, Positron emission tomography; PSMA, Prostate-specific membrane antigen; RA, Radioactivity; RGD, Arginyl-glycyl-aspartic acid; scFv, Single-chain variable fragment; SDF-1, Stromal cell-derived factor-1; SLC5a, Sodium/glucose cotransporter-5a; TAG-72, Tumor-associated glycoprotein-72; TGF-β, Transforming growth factor-β; TKR, Tyrosine kinase receptor; TM, Transmembrane; TNF-α, Tumor necrosis factor-α; TRPM8,

Transient receptor potential cation channel subfamily M member 8; uPAR, Urokinase-type plasminogen activator receptor; VEGF(R), Vascular endothelial growth factor (receptor).

Author Contributions

Conceived and designed the content of the manuscript and the figures: MCB, SWLdeG, HAJMP, and CFMS. Provided immunohistochemical illustrations: HAJMP. Wrote the first draft of the manuscript: SWLdeG and MCB. Contributed to the writing of the manuscript: LJACH and PJKK. Made critical revisions and approved the final version of the manuscript: MCB, SWLdeG, LJACH, CJHvdeV, PJKK, ALV, and CFMS.

REFERENCES

1. Gerber DE. Targeted therapies: a new generation of cancer treatments. *Am Fam Physician*. 2008;77:311–319.
2. Ciavarella S, Milano A, Dammacco F, Silvestris F. Targeted therapies in cancer. *BioDrugs*. 2010;24:77–88.
3. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. *MAbs*. 2015;7:9–14.
4. Almen MS, Nordstrom KJ, Fredriksson R, Schioth HB. Mapping the human membrane proteome: a majority of the human membrane proteins can be classified according to function and evolutionary origin. *BMC Biol*. 2009;7:50.
5. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? *Nat Rev Drug Discov*. 2006;5:993–996.
6. Rosenberg SA. Finding suitable targets is the major obstacle to cancer gene therapy. *Cancer Gene Ther*. 2014;21:45–47.
7. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. *Clin Cancer Res*. 2009;15:5323–5337.
8. Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. *Science*. 1972;175:720–731.
9. Chou KC, Elrod DW. Prediction of membrane protein types and subcellular locations. *Proteins*. 1999;34:137–153.
10. Arcangeli A, Crociani O, Lastraioli E, Masi A, Pillozzi S, Becchetti A. Targeting ion channels in cancer: a novel frontier in antineoplastic therapy. *Curr Med Chem*. 2009;16:66–93.
11. Li M, Xiong ZG. Ion channels as targets for cancer therapy. *Int J Physiol Pathophysiol Pharmacol*. 2011;3:156–166.
12. Sheng Q, Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. *Br J Cancer*. 2011;104:1241–1245.
13. Blok EJ, Kuppen PJ, van Leeuwen JE, Sier CF. Cytoplasmic overexpression of HER2: a key factor in colorectal cancer. *Clin Med Insights Oncol*. 2013;7:41–51.
14. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. *Nat Rev Cancer*. 2010;10:165–180.
15. Tandon M, Vemula SV, Mittal SK. Emerging strategies for EphA2 receptor targeting for cancer therapeutics. *Expert Opin Ther Targets*. 2011;15:31–51.
16. Annunziata CM, Kohn EC, LoRusso P, et al. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. *Invest New Drugs*. 2013;31:77–84.
17. Rosenthal EL, Warram JM, de BE, et al. Successful translation of fluorescence navigation during oncologic surgery: a consensus report. *J Nucl Med*. 2016;57:144–150.
18. Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. *Cancer Metastasis Rev*. 2008;27:85–94.
19. Jin H, Yang R, Zheng Z, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. *Cancer Res*. 2008;68:4360–4368.
20. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. *Nat Rev Drug Discov*. 2008;7:504–516.
21. Mazzone M, Basilico C, Cavassa S, et al. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. *J Clin Invest*. 2004;114:1418–1432.
22. Lu RM, Chang YL, Chen MS, Wu HC. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. *Biomaterials*. 2011;32:3265–3274.

23. Burggraaf J, Kamerling IM, Gordon PB, et al. Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met. *Nat Med*. 2015;21(8):955–961.
24. Arnaldez FI, Helman LJ. Targeting the insulin growth factor receptor 1. *Hematol Oncol Clin North Am*. 2012;26:527–542.
25. Zhang H, Zeng X, Li Q, Gaillard-Kelly M, Wagner CR, Yee D. Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore. *Br J Cancer*. 2009;101:71–79.
26. Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, et al. Immuno-SPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. *J Nucl Med*. 2010;51:1565–1572.
27. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. *Mol Pharmacol*. 2003;63:1256–1272.
28. Vassilatis DK, Hohmann JG, Zeng H, et al. The G protein-coupled receptor repertoires of human and mouse. *Proc Natl Acad Sci U S A*. 2003;100:4903–4908.
29. Millar RP, Newton CL. The year in G protein-coupled receptor research. *Mol Endocrinol*. 2010;24:261–274.
30. Innamorati G, Valenti MT, Giovinazzo F, Dalle Carbonare L, Parenti M, Bassi C. Molecular approaches to target GPCRs in cancer therapy. *Pharmaceuticals*. 2011;4:567–589.
31. Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. *Nat Rev Drug Discov*. 2011;10:47–60.
32. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. *Nat Rev Cancer*. 2007;7:79–94.
33. Domanska UM, Kruizinga RC, Nagengast WB, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. *Eur J Cancer*. 2013;49:219–230.
34. Kuil J, Buckle T, van Leeuwen FW. Imaging agents for the chemokine receptor 4 (CXCR4). *Chem Soc Rev*. 2012;41:5239–5261.
35. Gonda K, Watanabe TM, Ohuchi N, Higuchi H. In vivo nano-imaging of membrane dynamics in metastatic tumor cells using quantum dots. *J Biol Chem*. 2010;285:2750–2757.
36. Radu A, Pichon C, Camparo P, et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. *N Engl J Med*. 2010;363:1621–1630.
37. Keereweer S, Van Driel PB, Robinson DJ, Lowik CW. Shifting focus in optical image-guided cancer therapy. *Mol Imaging Biol*. 2014;16:1–9.
38. Kuiper P, Verspaget HW, Biemond I, et al. Expression and ligand binding of bombesin receptors in pulmonary and intestinal carcinoids. *J Endocrinol Invest*. 2011;34:665–670.
39. Cascini GL, Cuccurullo V, Tamburrini O, Rotondo A, Mansi L. Peptide imaging with somatostatin analogues: more than cancer probes. *Curr Radiopharm*. 2013;6:36–40.
40. Kossatz S, Behe M, Mansi R, et al. Multifactorial diagnostic NIR imaging of CCK2R expressing tumors. *Biomaterials*. 2013;34:5172–5180.
41. Heine M, Nollau P, Masslo C, et al. Investigations on the usefulness of CEACAMs as potential imaging targets for molecular imaging purposes. *PLoS One*. 2011;6:e28030.
42. Blumenthal RD, Leon E, Hansen HJ, Goldenberg DM. Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. *BMC Cancer*. 2007;7:2.
43. Saadatmand S, de Kruijf EM, Sajet A, et al. Expression of cell adhesion molecules and prognosis in breast cancer. *Br J Surg*. 2013;100(2):252–260.
44. Goldenberg DM. Carcinoembryonic antigen as a target cancer antigen for radiolabeled antibodies: prospects for cancer imaging and therapy. *Tumour Biol*. 1995;16:62–73.
45. Zaman MB, Baral TN, Jakubek ZJ, et al. Single-domain antibody bioconjugated near-IR quantum dots for targeted cellular imaging of pancreatic cancer. *J Nanosci Nanotechnol*. 2011;11:3757–3763.
46. Tiernan JP, Perry SL, Verghese ET, et al. Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. *Br J Cancer*. 2013;108:662–667.
47. Boonstra MC, Tolner B, Schaafsma BE, et al. Preclinical evaluation of a novel CEA-targeting near-infrared fluorescent tracer delineating colorectal and pancreatic tumors. *Int J Cancer*. 2015;137:1910–1920.
48. Winter MJ, Nagtegaal ID, van Krieken JH, Litvinov SV. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. *Am J Pathol*. 2003;163:2139–2148.
49. Spizzo G, Fong D, Wurm M, et al. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. *J Clin Pathol*. 2011;64:415–420.
50. Goossens-Beumer IJ, Zeestraten EC, Benard A, et al. Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer. *Br J Cancer*. 2014;110:2935–2944.
51. Simon M, Stefan N, Pluckthun A, Zangemeister-Wittke U. Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy. *Expert Opin Drug Deliv*. 2013;10:451–468.
52. Chaudry MA, Sales K, Ruf P, Lindhofer H, Winslet MC. EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges. *Br J Cancer*. 2007;96:1013–1019.

53. Punt CJ, Nagy A, Douillard JY, et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. *Lancet.* 2002;360:671–677.

54. Sebastian M, Kuemmel A, Schmidt M, Schmittel A. Catumaxomab: a bispecific trifunctional antibody. *Drugs Today (Barc).* 2009;45:589–597.

55. Entwistle J, Brown JG, Chooniedass S, Cizeau J, MacDonald GC. Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential. *Cancer Biother Radiopharm.* 2012;27:582–592.

56. van Rij CM, Lutje S, Frielink C, et al. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. *Eur J Nucl Med Mol Imaging.* 2013;40:1377–1383.

57. Zhu B, Wu G, Robinson H, et al. Tumor margin detection using quantitative NIRF molecular imaging targeting EpCAM validated by far red gene reporter iRFP. *Mol Imaging Biol.* 2013;15:560–568.

58. Rodriguez FJ, Lewis-Tuffin LJ, Anastasiadis PZ. E-cadherin's dark side: possible role in tumor progression. *Biochim Biophys Acta.* 2012;1826:23–31.

59. Blaschuk OW, Devemy E. Cadherins as novel targets for anti-cancer therapy. *Eur J Pharmacol.* 2009;625:195–198.

60. Rosivatz E, Becker I, Bamba M, et al. Neoexpression of N-cadherin in E-cadherin positive colon cancers. *Int J Cancer.* 2004;111:711–719.

61. Hynes RO. Integrins: bidirectional, allosteric signaling machines. *Cell.* 2002; 110:673–687.

62. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. *Nat Rev Cancer.* 2010;10:9–22.

63. Peters IT, Hilders CG, Sier CF, et al. Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue. *Arch Gynecol Obstet.* 2016;294(2): 385–393.

64. De Geus SW, Boogerd LS, Swijnenburg RJ, et al. Selecting tumor-specific molecular targets in pancreatic adenocarcinoma: paving the way for image-guided pancreatic surgery. *Mol Imaging Biol.* 2016.

65. Danhier F, Le BA, Preat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. *Mol Pharm.* 2012;9:2961–2973.

66. Bunschoten A, Buckle T, Visser NL, et al. Multimodal interventional molecular imaging of tumor margins and distant metastases by targeting alphavbeta3 integrin. *Chembiochem.* 2012;13:1039–1045.

67. Verbeek FP, Van der Vorst JR, Tummers QR, et al. Near-infrared fluorescence imaging of both colorectal cancer and ureters using a low-dose integrin targeted probe. *Ann Surg Oncol.* 2014;21:528–537.

68. Denmeade SR, Mhaka AM, Rosen DM, et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. *Sci Transl Med.* 2012;4:140ra86.

69. Humblet V, Lapidus R, Williams LR, et al. High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. *Mol Imaging.* 2005;4:448–462.

70. Bander NH. Technology insight: monoclonal antibody imaging of prostate cancer. *Nat Clin Pract Urol.* 2006;3:216–225.

71. Shen D, Xie F, Edwards WB. Evaluation of phage display discovered peptides as ligands for prostate-specific membrane antigen (PSMA). *PLoS One.* 2013;8:e68339.

72. Wang X, Ma D, Olson WC, Heston WD. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. *Mol Cancer Ther.* 2011;10:1728–1739.

73. Hrkach J, Von Hoff D, Mukkaram AM, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. *Sci Transl Med.* 2012;4:128ra39.

74. Wickstrom M, Larsson R, Nygren P, Gullbo J. Aminopeptidase N (CD13) as a target for cancer chemotherapy. *Cancer Sci.* 2011;102:501–508.

75. Corti A, Curnis F. Tumor vasculature targeting through NGR peptide-based drug delivery systems. *Curr Pharm Biotechnol.* 2011;12:1128–1134.

76. Wang RE, Niu Y, Wu H, Hu Y, Cai J. Development of NGR-based anti-cancer agents for targeted therapeutics and imaging. *Anticancer Agents Med Chem.* 2012; 12:76–86.

77. Zou M, Zhang L, Xie Y, Xu W. NGR-based strategies for targeting delivery of chemotherapeutics to tumor vasculature. *Anticancer Agents Med Chem.* 2012;12:239–246.

78. Ma W, Kang F, Wang Z, et al. (99m)Tc-labeled monomeric and dimeric NGR peptides for SPECT imaging of CD13 receptor in tumor-bearing mice. *Amino Acids.* 2013;44:1337–1345.

79. Chen L, Sun W, Li J, et al. The first ratiometric fluorescent probes for aminopeptidase N cell imaging. *Org Biomol Chem.* 2013;11:378–382.

80. Netzel-Arnett S, Hooper JD, Szabo R, et al. Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. *Cancer Metastasis Rev.* 2003;22:237–258.

81. LeBeau AM, Lee M, Murphy ST, et al. Imaging a functional tumorigenic biomarker in the transformed epithelium. *Proc Natl Acad Sci U S A.* 2013;110:93–98.

82. Ji T, Zhao Y, Wang J, et al. Tumor fibroblast specific activation of a hybrid ferritin nanocage-based optical probe for tumor microenvironment imaging. *Small.* 2013;9:2427–2431.

83. Ruger R, Tansi FL, Rabenhold M, et al. In vivo near-infrared fluorescence imaging of FAP-expressing tumors with activatable FAP-targeted, single-chain Fv-immunoliposomes. *J Control Release.* 2014;186:1–10.

84. Uhland K. Matriptase and its putative role in cancer. *Cell Mol Life Sci.* 2006; 63:2968–2978.

85. Duffy MJ, McKiernan E, O'Donovan N, McGowan PM. Role of ADAMs in cancer formation and progression. *Clin Cancer Res.* 2009;15:1140–1144.

86. Sano K, Temma T, Kuge Y, et al. Radioimmunodetection of membrane type-1 matrix metalloproteinase relevant to tumor malignancy with a pre-targeting method. *Biol Pharm Bull.* 2010;33:1589–1595.

87. Keereweer S, Mieog JS, Mol IM, et al. Detection of oral squamous cell carcinoma and cervical lymph node metastasis using activatable near-infrared fluorescence agents. *Arch Otolaryngol Head Neck Surg.* 2011;137:609–615.

88. Shimizu Y, Temma T, Sano K, Ono M, Saji H. Development of membrane type-1 matrix metalloproteinase-specific activatable fluorescent probe for malignant tumor detection. *Cancer Sci.* 2011;102:1897–1903.

89. Whitley MJ, Cardona DM, Lazarides AL, et al. A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. *Sci Transl Med.* 2016;8:320ra4.

90. McDonald PC, Winum JY, Supuran CT, Dedhar S. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. *Oncotarget.* 2012;3:84–97.

91. Sier CF, Gelderman KA, Prins FA, Gorter A. Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation. *Int J Cancer.* 2004;109:900–908.

92. Brouwers AH, Buijs WC, Oosterwijk E, et al. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. *Clin Cancer Res.* 2003;9:3953S–3960S.

93. van Brussel AS, Adams A, Vermeulen JF, et al. Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast. *Breast Cancer Res Treat.* 2013;140:263–272.

94. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. *J Cell Physiol.* 2005;202:654–662.

95. Beck B, Bidaux G, Bavencoffe A, et al. Prospects for prostate cancer imaging and therapy using high-affinity TRPM8 activators. *Cell Calcium.* 2007;41:285–294.

96. Yee NS, Chan AS, Yee JD, Yee RK. TRPM7 and TRPM8 ion channels in pancreatic adenocarcinoma: potential roles as cancer biomarkers and targets. *Scientifica (Cairo).* 2012;2012:415158.

97. Ghosh SK, Uchida M, Yoo B, et al. Targeted imaging of breast tumor progression and therapeutic response in a human uMUC-1 expressing transgenic mouse model. *Int J Cancer.* 2013;132:1860–1867.

98. Martinez O, Bellard E, Golzio M, et al. Direct validation of aptamers as powerful tools to image solid tumor. *Nucleic Acid Ther.* 2014;24(3):217–225.

99. Hischemoller A, Walter C, Weiler V, et al. Labeling of anti-MUC-1 binding single chain Fv fragments to surface modified upconversion nanoparticles for an initial in vivo molecular imaging proof of principle approach. *Int J Mol Sci.* 2012; 13:4153–4167.

100. Shahbazi-Gahrouei D, Abdolahi M. Superparamagnetic iron oxide-C595: potential MR imaging contrast agents for ovarian cancer detection. *J Med Phys.* 2013;38:198–204.

101. Chen H, Zhao J, Zhang M, Yang H, Ma Y, Gu Y. MUC1 aptamer-based near-infrared fluorescence probes for tumor imaging. *Mol Imaging Biol.* 2015; 17(1):38–48.

102. Weidle UH, Scheuer W, Eggle D, Klostermann S, Stockinger H. Cancer-related issues of CD147. *Cancer Genomics Proteomics.* 2010;7:157–169.

103. Bordador LC, Li X, Toole B, et al. Expression of emmprin by oral squamous cell carcinoma. *Int J Cancer.* 2000;85:347–352.

104. Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. *Clin Exp Metastasis.* 2003;20:161–169.

105. Sier CF, Zuidwijk K, Zijlmans HJ, et al. EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma. *Int J Cancer.* 2006; 118:2991–2998.

106. Kim H, Zhai G, Samuel SL, et al. Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma. *Mol Cancer Ther.* 2012;11:405–415.

107. Sugyo A, Tsuji AB, Sudo H, et al. Evaluation of (89)Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer. *PLoS One.* 2013;8:e61230.

108. Ni M, Zhang Y, Lee AS. Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting. *Biochem J.* 2011;434:181–188.

109. Li Z, Zhang L, Zhao Y, et al. Cell-surface GRP78 facilitates colorectal cancer cell migration and invasion. *Int J Biochem Cell Biol.* 2013;45:987–994.

110. Baptista MZ, Sarian LO, Vassallo J, Pinto GA, Soares FA, de Souza GA. Prognostic significance of GRP78 expression patterns in breast cancer patients receiving adjuvant chemotherapy. *Int J Biol Markers.* 2011;26:188–196.

111. Delie F, Petignat P, Cohen M. GRP78 protein expression in ovarian cancer patients and perspectives for a drug-targeting approach. *J Oncol.* 2012;2012: 468615.

112. Thornton M, Aslam MA, Tweedle EM, et al. The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer. *Int J Cancer*. 2013;133(6):1408–1418.

113. Wang H, Li D, Liu S, et al. Small-animal PET imaging of pancreatic cancer xenografts using a 64Cu-labeled monoclonal antibody, MAb159. *J Nucl Med*. 2015;56:908–913.

114. Rossi E, Lopez-Novoa JM, Bernabeu C. Endoglin involvement in integrin-mediated cell adhesion as a putative pathogenic mechanism in hereditary hemorrhagic telangiectasia type 1 (HHT1). *Front Genet*. 2014;5:457.

115. Rosen LS, Hurwitz HI, Wong MK, et al. A phase I first-in-human study of TRC105 (anti-endoglin antibody) in patients with advanced cancer. *Clin Cancer Res*. 2012;18(17):4820–4829.

116. Hong H, Zhang Y, Orbay H, et al. Positron emission tomography imaging of tumor angiogenesis with a (61/64)Cu-labeled F(ab')(2) antibody fragment. *Mol Pharm*. 2013;10:709–716.

117. Okamoto T, Schwab RB, Scherer PE, Lisanti MP. Analysis of the association of proteins with membranes. *Curr Protoc Cell Biol*. 2001;Chapter 5:Unit5.4.

118. Taylor DR, Hooper NM. GPI-anchored proteins in health and disease. In: Vidal CJ, ed. *Post-Translational Modifications in Health and Disease*. New York: Springer; 2011:39–55.

119. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. *Clin Cancer Res*. 2004;10:3937–3942.

120. Tang Z, Feng M, Gao W, et al. A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface. *Mol Cancer Ther*. 2013;12:416–426.

121. Golfier S, Kopitz C, Kahnert A, et al. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. *Mol Cancer Ther*. 2014;13:1537–1548.

122. Saeki N, Gu J, Yoshida T, Wu X. Prostate stem cell antigen: a Jekyll and Hyde molecule? *Clin Cancer Res*. 2010;16:3533–3538.

123. Ferraris GM, Sidenius N. Urokinase plasminogen activator receptor: a functional integrator of extracellular proteolysis, cell adhesion, and signal transduction. *Semin Thromb Hemost*. 2013;39:347–355.

124. Boonstra MC, Verspaget HW, Ganesh S, et al. Clinical applications of the urokinase receptor (uPAR) for cancer patients. *Curr Pharm Des*. 2011;17:1890–1910.

125. Boonstra MC, Verbeek FP, Mazar AP, et al. Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study. *BMC Cancer*. 2014;14:269.

126. O'Halloran TV, Ahn R, Hankins P, Swindell E, Mazar AP. The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target. *Theranostics*. 2013;3:496–506.

127. Persson M, Kjaer A. Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications. *Clin Physiol Funct Imaging*. 2013;33:329337.

128. Boonstra MC, Van Driel PB, Van Willigen DM, et al. uPAR-targeted multimodal tracer for pre- and operative imaging in cancer surgery. *Oncotarget*. 2015;6(16):14260–14273.

129. Mazar AP, Ahn RW, O'Halloran TV. Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic. *Curr Pharm Des*. 2011;17:1970–1978.

130. Persson M, Skovgaard D, Brandt-Larsen M, et al. First-in-human uPAR PET: imaging of cancer aggressiveness. *Theranostics*. 2015;5:1303–1316.

131. Juhl K, Christensen A, Persson M, Ploug M, Kjaer A. Peptide-based optical uPAR imaging for surgery: in vivo testing of ICG-Glu-Glu-AE105. *PLoS One*. 2016;11:e0147428.

132. Leamon CP, Low PS. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. *Proc Natl Acad Sci U S A*. 1991;88:5572–5576.

133. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. *Adv Drug Deliv Rev*. 2000;41:147–162.

134. Lu Y, Sega E, Leamon CP, Low PS. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. *Adv Drug Deliv Rev*. 2004;56:1161–1176.

135. Boogerd LS, Boonstra MC, Beck AJ, et al. Concordance of folate receptor-alpha expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients. *Oncotarget*. 2016;7(14):17442–17454.

136. Kalber TL, Kamaly N, So PW, et al. A low molecular weight folate receptor targeted contrast agent for magnetic resonance tumor imaging. *Mol Imaging Biol*. 2011;13:653–662.

137. Kelderhouse LE, Chelvam V, Wayua C, et al. Development of tumor-targeted near infrared probes for fluorescence guided surgery. *Bioconjug Chem*. 2013;24:1075–1080.

138. van Dam GM, Themelis G, Crane LM, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. *Nat Med*. 2011;17(10):1315–1319.

139. Hoogstins CE, Tummers QR, Gaarenstroom KN, et al. A novel tumor-specific agent for intraoperative near-infrared fluorescence imaging: a translational study in healthy volunteers and patients with ovarian cancer. *Clin Cancer Res*. 2016;22:2929–2938.

140. Sohail A, Sun Q, Zhao H, Bernardo MM, Cho JA, Fridman R. MT4-(MMP17) and MT6-MMP (MMP25), A unique set of membrane-anchored matrix metalloproteinases: properties and expression in cancer. *Cancer Metastasis Rev*. 2008;27:289–302.

141. Sun Q, Weber CR, Sohail A, et al. MMP25 (MT6-MMP) is highly expressed in human colon cancer, promotes tumor growth, and exhibits unique biochemical properties. *J Biol Chem*. 2007;282:21998–22010.

142. Velasco G, Cal S, Merlos-Suarez A, et al. Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors. *Cancer Res*. 2000;60:877–882.

143. Host L, Paye A, Detry B, et al. The proteolytic activity of MT4-MMP is required for its pro-angiogenic and pro-metastatic promoting effects. *Int J Cancer*. 2012;131:1537–1548.

144. Van Oosten M, Crane LM, Bart J, van Leeuwen FW, van Dam GM. Selecting potential targetable biomarkers for imaging purposes in colorectal cancer using target selection criteria (TASC): a novel target identification tool. *Transl Oncol*. 2011;4:71–82.

145. Hendriks BS, Klinz SG, Reynolds JG, Espelin CW, Gaddy DF, Wickham TJ. Impact of tumor HER2/ERBB2 expression level on HER2-targeted liposomal doxorubicin-mediated drug delivery: multiple low-affinity interactions lead to a threshold effect. *Mol Cancer Ther*. 2013;12(9):1816–1828.

146. van Driel PB, Van der Vorst JR, Verbeek FP, et al. Intraoperative fluorescence delineation of head and neck cancer with a fluorescent anti-epidermal growth factor receptor nanobody. *Int J Cancer*. 2014;134:2663–2673.

147. Wilken JA, Baron AT, Maihle NJ. The epidermal growth factor receptor conundrum. *Cancer*. 2010;117:2358–2360.

148. D'Souza-Schorey C, Clancy JW. Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. *Genes Dev*. 2012;26:1287–1299.

149. Paulick MG, Bertozzi CR. The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins. *Biochemistry*. 2008;47:6991–7000.

150. Kelemen LE. The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? *Int J Cancer*. 2006;119:243–250.

151. Fernandez C, Clark K, Burrows L, Schofield NR, Humphries MJ. Regulation of the extracellular ligand binding activity of integrins. *Front Biosci*. 1998;3:d684–d700.

152. Tummers QR, Hoogstins CE, Gaarenstroom KN, et al. Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17. *Oncotarget*. 2016:32144–32155.

153. Tjalma JJ, Garcia-Allende PB, Hartmans E, et al. Molecular fluorescence endoscopy targeting vascular endothelial growth factor a for improved colorectal polyp detection. *J Nucl Med*. 2016;57:480–485.

154. Paauwe M, Ten DP, Hawinkels LJ. Endoglin for tumor imaging and targeted cancer therapy. *Expert Opin Ther Targets*. 2013;17:421–435.

155. Optical Imaging Market—Technology Trends and Applications of Optical Coherence Tomography (OCT), Hyper Spectral Imaging (HSI), Near Infrared Spectroscopy (NIRS) and Photo-Acoustic Tomography (PAT) in Clinical Diagnostics, Clinical Research and Life Sciences With Market Landscape Analysis—(2013–2018). MD 1354. 2013. Available at: marketsandmarkets.com.

156. Weber J, Haberkorn U, Mier W. Cancer stratification by molecular imaging. *Int J Mol Sci*. 2015;16:4918–4946.

157. Heukers R, van Bergen en Henegouwen PM, Oliveira S. Nanobody-photosensitizer conjugates for targeted photodynamic therapy. *Nanomedicine*. 2014;10:1441–1451.

158. Fleetwood F, Klint S, Hanze M, et al. Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic affibody molecules results in dramatically improved affinity. *Sci Rep*. 2014;4:7518.

159. Benedetto S, Pulito R, Crich SG, et al. Quantification of the expression level of integrin receptor alpha(v)beta3 in cell lines and MR imaging with antibody-coated iron oxide particles. *Magn Reson Med*. 2006;56:711–716.

160. Aprikian AG, Han K, Chevalier S, Bazinet M, Viallet J. Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells. *J Mol Endocrinol*. 1996;16:297–306.

161. Zavada J, Zavadova Z, Zat'ovicova M, Hyrsl L, Kawaciuk I. Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. *Br J Cancer*. 2003;89:1067–1071.

162. Kos J, Nielsen HJ, Krasovec M, et al. Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. *Clin Cancer Res*. 1998;4:1511–1516.

163. Levin LV, Griffin TW, Childs LR, Davis S, Haagensen DE Jr. Comparison of multiple anti-CEA immunotoxins active against human adenocarcinoma cells. *Cancer Immunol Immunother*. 1987;24:202–206.

164. van Hensbergen Y, Broxterman HJ, Hanemaaijer R, et al. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. *Clin Cancer Res*. 2002;8:3747–3754.

165. Xu Y, Wellner D, Scheinberg DA. Cryptic and regulatory epitopes in CD13/aminopeptidase N. *Exp Hematol*. 1997;25:521–529.

166. Kajita M, Itoh Y, Chiba T, et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. *J Cell Biol*. 2001;153:893–904.

167. Nestor M, Ekberg T, Dring J, et al. Quantification of CD44v6 and EGFR expression in head and neck squamous cell carcinomas using a single-dose radio-immunoassay. *Tumour Biol*. 2007;28:253–263.

168. Guo P, You JO, Yang J, Moses MA, Auguste DT. Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity. *Biomaterials*. 2012;33:8104–8110.

169. Imai Y, Leung CK, Friesen HG, Shiu RP. Epidermal growth factor receptors and effect of epidermal growth factor on growth of human breast cancer cells in long-term tissue culture. *Cancer Res*. 1982;42:4394–4398.

170. Todeschini P, Cocco E, Bellone S, et al. Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. *Br J Cancer*. 2011;105:1176–1182.

171. Brand FX, Ravanel N, Gauchez AS, et al. Prospect for anti-HER2 receptor therapy in breast cancer. *Anticancer Res*. 2006;26:463–470.

172. Jäger M, Schoberth A, Ruf P, Hess J, Lindhofer H. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. *Cancer Res*. 2009;69:4270–4276.

173. Hanata K, Yamaguchi N, Yoshikawa K, et al. Soluble EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates the migration of HEp-2 human laryngeal carcinoma cells, accompanied by increased MMP-2 production in fibroblasts. *Arch Histol Cytol*. 2007;70:267–277.

174. Kim H, Zhai G, Liu Z, et al. EMMPRIN as a novel target for pancreatic cancer therapy. *Anticancer Drugs*. 2011;22:864–874.

175. Hawinkels LJ, Kuiper P, Wiercinska E, et al. Matrix metalloproteinase-14 (MT1–MMP)-mediated endoglin shedding inhibits tumor angiogenesis. *Cancer Res*. 2010;70:4141–4150.

176. Lastres P, Letamendia A, Zhang H, et al. Endoglin modulates cellular responses to TGF-beta 1. *J Cell Biol*. 1996;133:1109–1121.

177. Petsch S, Gires O, Ruttinger D, et al. Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110. *MAbs*. 2011;3:31–37.

178. Rao CG, Chianese D, Doyle GV, et al. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. *Int J Oncol*. 2005;27:49–57.

179. Sugiyama N, Gucciardo E, Tatti O, et al. EphA2 cleavage by MT1-MMP triggers single cancer cell invasion via homotypic cell repulsion. *J Cell Biol*. 2013; 201:467–484.

180. Hammond SA, Lutterbuese R, Roff S, et al. Selective targeting and potent control of tumor growth using an EphA2/CD3-bispecific single-chain antibody construct. *Cancer Res*. 2007;67:3927–3935.

181. Keane FM, Yao TW, Seelk S, et al. Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs. *FEBS Open Bio*. 2013;4:43–54.

182. Christiansen VJ, Jackson KW, Lee KN, Downs TD, McKee PA. Targeting inhibition of fibroblast activation protein-alpha and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments. *Neoplasia*. 2013;15:348–358.

183. Leung F, Dimitromanolakis A, Kobayashi H, Diamandis EP, Kulasingam V. Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients. *Clin Biochem*. 2013;46(15):1462–1468.

184. Forster MD, Ormerod MG, Agarwal R, Kaye SB, Jackman AL. Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells. *Cytometry A*. 2007;71:945–950.

185. Chen M, Zhang Y, Yu VC, Chong YS, Yoshioka T, Ge R. Isthmin targets cell-surface GRP78 and triggers apoptosis via induction of mitochondrial dysfunction. *Cell Death Differ*. 2014;21:797–810.

186. Jin X, Hirosaki T, Lin CY, et al. Production of soluble matriptase by human cancer cell lines and cell surface activation of its zymogen by trypsin. *J Cell Biochem*. 2005;95:632–647.

187. Zhang J, Qiu S, Zhang Y, et al. Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P. *Anticancer Res*. 2012;32:5151–5158.

188. Yang JJ, Yang JH, Kim J, et al. Soluble c-Met protein as a susceptible biomarker for gastric cancer risk: a nested case-control study within the Korean Multicenter Cancer Cohort. *Int J Cancer*. 2013;132:2148–2156.

189. Wang Q, Dierkes R, Kaufmann R, Cremer C. Quantitative analysis of individual hepatocyte growth factor receptor clusters in influenza A virus infected human epithelial cells using localization microscopy. *Biochim Biophys Acta*. 2014; 1838:1191–1198.

190. Thathiah A, Carson DD. MT1-MMP mediates MUC1 shedding independent of TACE/ADAM17. *Biochem J*. 2004;382:363–373.

191. Danielczyk A, Stahn R, Faulstich D, et al. PankoMab: a potent new generation anti-tumour MUC1 antibody. *Cancer Immunol Immunother*. 2006;55:1337–1347.

192. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. *Clin Cancer Res*. 2004; 10:3943–3953.

193. Xiao Z, Adam BL, Cazares LH, et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. *Cancer Res*. 2001;61:6029–6033.

194. Freire T, Medeiros A, Reis CA, Real FX, Osinaga E. Biochemical characterization of soluble Tn glycoproteins from malignant effusions of patients with carcinomas. *Oncol Rep*. 2003;10:1577–1585.

195. Sier CF, Sidenius N, Mariani A, et al. Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. *Lab Invest*. 1999;79:717–722.

196. Lengyel E, Wang H, Gum R, Simon C, Wang Y, Boyd D. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade. *Oncogene*. 1997;14:2563–2573.